Vibalogics, a global contract development and manufacturing organization (CDMO) that specializes in the production of virotherapy products, said it will manufacture additional clinical trial material for the lead COVID-19 vaccine candidate currently in development by the Janssen Pharmaceutical Companies of Johnson & Johnson.
 
From its GMP accredited facility in Cuxhaven, Germany, the company is contracted to manufacture multiple batches, which will result in many thousands of doses of an investigational COVID-19 vaccine candidate.
 
“This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19,” said Stefan Beyer, managing director and chief executive officer, Vibalogics. “The business has reacted quickly and efficiently to accommodate this request. With the devotion of our team, and understanding from our customers, we have successfully managed to fulfil this new requirement alongside all of our existing business commitments.”
 
Offering process development, manufacturing, testing and fill-finish services, Vibalogics has over 15 years’ experience working with live viruses.
 
The CDMO has recently invested in new equipment to handle larger clinical batches including a new filling line capable of filling and labelling more than 30,000 vials per batch.
                                                                                                                
In May 2019, Vibalogics was acquired by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, allowing the CDMO to further its growth strategy with plans to extend its footprint in the U.S. The company is set to establish a commercial facility in North America for oncolytic viruses, viral vectors for gene therapy approaches and viral vector vaccines in the near future.